Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HEALTHEQUITY, INC. Director's Dealing 2017

Apr 5, 2017

30722_dirs_2017-04-05_243ca9d3-6d8a-49f2-9ae4-d0956f59092e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEALTHEQUITY INC (HQY)
CIK: 0001428336
Period of Report: 2017-04-03

Reporting Person: Kessler Jon (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-04-03 Common Stock M 20000 $1.25 Acquired 440000 Direct
2017-04-03 Common Stock S 20000 $41.8534 Disposed 420000 Direct
2017-04-04 Common Stock M 10000 $1.25 Acquired 430000 Direct
2017-04-04 Common Stock S 10000 $43.0104 Disposed 420000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-04-03 Stock Option (right to buy) $1.25 M 20000 Disposed 2021-08-08 Common Stock (20000) Direct
2017-04-04 Stock Option (right to buy) $1.25 M 10000 Disposed 2021-08-08 Common Stock (10000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $41.28 2027-03-27 Common Stock (69639) 69639 Direct
Stock Option (right to buy) $14 2024-07-30 Common Stock (120000) 120000 Direct

Footnotes

F1: The option exercises and subsequent sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2016.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.52 to $42.43, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.95 to $43.14, inclusive.

F4: The option is immediately exercisable.

F5: The option becomes exercisable as to 17,409 shares on March 27, 2018 and in three annual installments of 17,410 shares on March 27, 2019, 2020 and 2021.